Please login to the form below

Tcelna

This page shows the latest Tcelna news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA drops Ono-partnered multiple sclerosis drug

It also has a licensing deal in place for Tcelna (imilecleucel-T), a personalised treatment for secondary-progressive MS developed by Opexa Therapeutics that is in phase IIb testing with

Latest news

Currencies hit Merck Serono sales but firm says it is 'on course'

Overall groups sales down to €2.84bn for second quarter of 2013
Merck KGaA to meet 2014 financial targets one year early

and recently-licensed MS drug Tcelna (imilecleucel-T) following the decision to drop brain and lung cancer prospect cilengitide from development in the first quarter.
Merck KGaA and Opexa enter MS deal

Will develop personalised T-cell based medicine Tcelna. Merck KGaA has agreed a deal with Opexa Therapeutics to develop and commercialise a new personalised treatment for multiple sclerosis (MS). ... During the SPMS trial, patients undergo two annual

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Pharma deals during February 2013

sales. In the other option deal, Merck Serono has acquired an option over Opexa Therapeutics' phase IIb Tcelna (imilecleucel-T) vaccine for MS (for all territories except Japan). ... Tcelna is being developed as a personalised therapy specifically

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Competitive salary plus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Manager – Healthcare advertising: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Events Executive: DOE

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Client Services Director- Flexible Working: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Jet Off with Maloff Protect

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...